Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER vs CALCIUM CHLORIDE 10%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium is the principal intracellular cation and is essential for maintaining cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose provides calories and may prevent ketosis.
Calcium chloride dissociates to provide calcium ions, which are essential for myocardial contractility, nerve impulse transmission, and blood coagulation. It antagonizes the cardiotoxic effects of hyperkalemia by stabilizing cardiac cell membrane potential.
Treatment of hypokalemia,Prevention of hypokalemia,Replacement of potassium losses,Provision of fluid and caloric needs when potassium supplementation is required
Emergency treatment of hypocalcemic tetany,Cardiac resuscitation in the presence of hyperkalemia or hypocalcemia,Treatment of calcium channel blocker overdose,Treatment of magnesium sulfate overdose,Management of acute hypermagnesemia,Used in cardiac surgery to reverse citrate anticoagulation
Intravenous; typical adult dose is 10-20 m Eq/hour, not exceeding 40 m Eq/hour or 150 m Eq/day, with continuous cardiac monitoring and serum potassium monitoring.
IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min; may be repeated every 1-3 days based on serum calcium levels.
The elimination half-life of potassium is not applicable in the traditional sense because potassium is an endogenous ion under tight homeostatic control. After intravenous infusion of a potassium load, the plasma concentration declines with a distribution phase of about 1-2 hours, followed by a slower elimination phase reflecting cellular uptake and renal excretion, with a terminal half-life of approximately 6-8 hours in patients with normal renal function.
Terminal half-life ~4-6 hours for rapid distribution phase; prolonged in renal impairment (up to 24-48 hours).
Potassium is not metabolized; it is excreted primarily by the kidneys. Dextrose undergoes glycolysis and oxidation to carbon dioxide and water.
Calcium chloride is not metabolized; it is excreted primarily in the urine with reabsorption regulated by the kidneys and parathyroid hormone.
Renal: >90% of potassium intake is excreted by the kidneys, primarily via distal tubular secretion; fecal: <10%; minor sweat losses. In this formulation (KCl 0.22% in D5W), the potassium content is 2 m Eq per 100 m L (approximately 20 m Eq/L).
Primarily renal (>80% as ionized calcium); minor fecal elimination (10-20%) via endogenous secretion; negligible biliary excretion.
Negligible (<5%). Potassium is not significantly bound to plasma proteins; it exists as free ion in serum.
Approximately 45-50% bound to albumin; 10-15% complexed with citrate, phosphate, or bicarbonate.
Approximately 0.5-0.6 L/kg (total body water); reflects distribution throughout extracellular and intracellular spaces. Potassium is predominantly intracellular (98% of total body potassium is in cells); Vd for administered potassium is large due to cellular uptake.
0.3-0.4 L/kg (primarily extracellular fluid). Increased in hypocalcemia or hypoalbuminemia.
Intravenous: 100% (complete bioavailability). Oral: about 90% absorbed; however, this formulation is for IV administration only.
IV/IO: 100%. Not administered orally for systemic effect due to GI irritation and poor absorption; oral bioavailability is negligible (<1%) if ingested.
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: reduce total daily dose by 25-50%; GFR < 10 m L/min: reduce dose by 50-75% and monitor potassium closely. Avoid if anuria.
e GFR <30 m L/min: Use with caution, reduce dose by 50% and monitor serum calcium closely; e GFR <15 m L/min: Avoid use if possible, if necessary use lowest effective dose with frequent monitoring.
No specific adjustment based on Child-Pugh score; however, monitor potassium levels and renal function closely due to potential hepatorenal syndrome.
No specific dose adjustment required for Child-Pugh class A, B, or C; monitor serum calcium due to potential for altered vitamin D metabolism.
Intravenous; 0.2-0.5 m Eq/kg/hour, not exceeding 1 m Eq/kg/hour or 40 m Eq/m²/hour; adjust based on serum potassium and clinical status.
IV: 10-20 mg/kg of elemental calcium (0.1-0.2 m L/kg of 10% solution) given slowly (not exceeding 0.5 m L/min). Maximum single dose: 500 mg (5 m L). May repeat in 4-6 hours if needed.
Cautious dosing: initial dose at lower end of adult range (10 m Eq/hour) with close monitoring of renal function and serum potassium due to decreased renal reserve and higher risk of hyperkalemia.
Start at lower end of dosing range (e.g., 500 mg IV), administer at a slower rate (over 10-15 minutes) due to higher risk of hypercalcemia and cardiovascular effects; monitor renal function and serum calcium frequently.
Potassium chloride injection concentrate must be diluted before use to avoid fatal hyperkalemia.
Rapid intravenous injection may cause cardiac arrest. Avoid extravasation as it causes severe tissue necrosis. Use with extreme caution in patients receiving digitalis glycosides due to risk of arrhythmias.
Hyperkalemia risk; monitor serum potassium levels,Cardiotoxicity; ECG monitoring recommended,Risk of extravasation; do not administer intramuscularly,Use with caution in renal impairment, adrenal insufficiency, or conditions predisposing to hyperkalemia,Do not administer if solution is discolored or contains particulate matter
Administer intravenously only; intramuscular or subcutaneous injection causes severe irritation and necrosis.,Use with caution in patients with renal impairment, sarcoidosis, or hypercalcemia.,Monitor serum calcium levels and electrocardiogram during administration.,Risk of bradycardia and arrhythmias, especially with concurrent digitalis therapy.,Rapid injection may cause vasodilation, hypotension, and cardiac arrest.
Hyperkalemia,Severe renal failure with oliguria or anuria,Adrenal insufficiency,Concomitant use of potassium-sparing diuretics,Crush syndrome,Severe hemolytic reactions
Hypercalcemia,Ventricular fibrillation during cardiac arrest (unless due to hypocalcemia),Severe hypercalciuria or calcinosis,Concurrent digitalis therapy (relative, may increase risk of arrhythmias)
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, tomatoes, potatoes, spinach, salt substitutes) while receiving this IV solution to prevent hyperkalemia.
Avoid excessive intake of oxalate-rich foods (spinach, rhubarb, beets) and phytate-rich foods (bran, whole grains) as they may bind calcium and reduce absorption. Also limit sodium-containing foods to prevent calcium loss via urine. No direct food interactions with intravenous administration.
Potassium chloride and dextrose are not known to be teratogenic. No fetal risks have been identified in any trimester. Dextrose is a physiological nutrient. Overdose or rapid infusion may cause maternal electrolyte imbalance potentially affecting fetus.
Animal reproduction studies have not been conducted with calcium chloride. It is not known whether calcium chloride can cause fetal harm when administered to a pregnant woman. Calcium is an essential mineral for fetal development; however, high doses may lead to hypercalcemia in the mother and fetus. In the first trimester, no specific teratogenic risk is documented; however, maternal hypercalcemia from excessive supplementation may interfere with placental calcium transport and fetal bone development. In the second and third trimesters, excessive doses may cause fetal hypoparathyroidism, hypercalcemia, and potential neonatal hypocalcemia due to suppression of the fetal parathyroid gland. Use only if clearly needed and with caution.
Potassium and dextrose are normal constituents of breast milk. No adverse effects anticipated. Use considered safe during breastfeeding. M/P ratio not established.
Calcium is excreted into breast milk. The M/P ratio for calcium is approximately 1.0 (range 0.9-1.1) reflecting passive diffusion and active transport. Intravenous calcium chloride administration may transiently increase maternal serum calcium levels, leading to a small increase in milk calcium concentration. However, this is unlikely to cause adverse effects in the breastfed infant. The American Academy of Pediatrics considers calcium supplementation compatible with breastfeeding. Use with caution and monitor infant for signs of hypercalcemia (e.g., constipation, irritability) if high doses are administered.
No dose adjustment required. Use standard adult dosing, adjusted for maternal weight and clinical status. Monitor for fluid overload and electrolyte disturbances.
Pregnancy is associated with increased plasma volume and enhanced renal clearance, potentially lowering serum calcium levels. However, calcium chloride is typically administered intravenously for acute hypocalcemia or cardiac resuscitation; no specific dose adjustments are recommended solely due to pregnancy. Use standard dosing based on the indication and severity of hypocalcemia, with close monitoring of serum calcium to avoid overdosage. The same caution applies: administer slowly (0.5-1 m L/min of 10% solution) and check ECG if rapid infusion.
This solution provides 22 m Eq/L of potassium chloride and 5% dextrose. Use with caution in patients with renal impairment, cardiac disease, or hyperkalemia. Monitor serum potassium levels closely; rate of infusion should not exceed 10 m Eq/hour typically. Avoid in patients with oliguria or anuria. Do not administer undiluted; container is for intravenous use only.
Calcium chloride 10% (100 mg/m L) provides 13.6 m Eq/10 m L of calcium. It is highly irritating; administer via central venous line to avoid severe tissue necrosis if extravasation occurs. Do not mix with bicarbonate or phosphate solutions. In cardiac arrest, consider dose of 500-1000 mg IV push (repeat q10min if needed). Contraindicated in digitalis toxicity due to risk of fatal arrhythmias.
This medication is given through a vein to provide potassium and sugar.,Tell your healthcare provider if you have kidney problems, heart disease, or are taking any other medications.,Report any symptoms of high potassium such as muscle weakness, irregular heartbeat, or tingling sensations.,You may experience pain or irritation at the IV site; inform your nurse if this occurs.,Do not stop or change the infusion rate on your own.
This medication is given intravenously to treat calcium deficiency or certain emergencies.,You may experience a warm sensation, metallic taste, or flushing during injection.,Report any burning, pain, or redness at the injection site immediately.,Avoid taking digoxin (digitalis) unless specifically instructed by your doctor.,Do not stop or change the dose without consulting your healthcare provider.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Calcium chloride, an intravenous calcium salt, directly increases serum ionized calcium levels, which can antagonize the pharmacodynamic effects of the calcium channel blocker manidipine. Manidipine inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced blood pressure. Elevated extracellular calcium from calcium chloride administration can overcome this blockade, potentially diminishing the antihypertensive efficacy of manidipine and increasing the risk of hypertensive urgency or elevated blood pressure."
"Calcium chloride, a source of calcium ions, can chelate with bisphosphonates such as risedronic acid in the gastrointestinal tract, forming insoluble complexes that reduce the oral absorption of risedronic acid. This interaction may lead to decreased serum concentrations of risedronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption. Patients may experience reduced bone mineral density or increased risk of fractures if the interaction is significant."
"Calcium chloride, a source of calcium ions, can chelate alendronic acid (a bisphosphonate) in the gastrointestinal tract, forming insoluble complexes that reduce the absorption of alendronic acid. This interaction can significantly decrease the systemic bioavailability and serum concentration of alendronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption and treating osteoporosis. Clinically, patients may experience reduced bone mineral density improvement or increased fracture risk if the drugs are co-administered."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER vs CALCIUM CHLORIDE 10%, answered by our medical review team.
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER is a Electrolyte Supplement that works by Potassium is the principal intracellular cation and is essential for maintaining cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose provides calories and may prevent ketosis.. CALCIUM CHLORIDE 10% is a Electrolyte Supplement that works by Calcium chloride dissociates to provide calcium ions, which are essential for myocardial contractility, nerve impulse transmission, and blood coagulation. It antagonizes the cardiotoxic effects of hyperkalemia by stabilizing cardiac cell membrane potential.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER and CALCIUM CHLORIDE 10% depend on the specific clinical indication. These are both Electrolyte Supplement agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous; typical adult dose is 10-20 m Eq/hour, not exceeding 40 m Eq/hour or 150 m Eq/day, with continuous cardiac monitoring and serum potassium monitoring.. The standard adult dose of CALCIUM CHLORIDE 10% is: IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min; may be repeated every 1-3 days based on serum calcium levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER and CALCIUM CHLORIDE 10% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Potassium chloride and dextrose are not known to be teratogenic. No fetal risks have been identified in any trimester. Dextrose is a physiological nutrient. Overdose or rapid infus. CALCIUM CHLORIDE 10% is classified as Category C. Animal reproduction studies have not been conducted with calcium chloride. It is not known whether calcium chloride can cause fetal harm when administered to a pregnant woman. Calc. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.